DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis

Information source: University of Cologne
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Invasive Aspergillosis

Intervention: caspofungin (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: University of Cologne

Official(s) and/or principal investigator(s):
Oliver A. Cornely, MD, Principal Investigator, Affiliation: Klinikum der Universität zu Köln


This study investigates the safety and tolerability as well as the efficacy and pharmacokinetics of caspofungin in four escalating dosages in adult patients with hematologic malignancies and proven or probable invasive aspergillosis.

Clinical Details

Official title: A Phase II Dose Escalation Study of Caspofungin in Patients With Invasive Aspergillosis

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Safety and Tolerability of Caspofungin in Four Escalating Dosages in Adult Patients With Hematologic Malignancies and Proven or Probable Invasive Aspergillosis

Secondary outcome: Efficacy of Caspofungin in Four Escalating Dosages in the Treatment of Proven or Probable Invasive Aspergillosis.

Detailed description: Due to its efficacy and a broad antifungal spectrum against relevant fungal pathogens, lack of cross-resistance to azoles and amphotericin B, documented efficacy against human Aspergillus infections, favorable pharmacokinetic properties, and excellent tolerability according to the current data, caspofungin is a highly promising candidate for improving the results of treatment of invasive fungal infections. Preclinical and clinical data indicate a dose dependent antifungal efficacy of caspofungin as well as of other echinocandins such as micafungin and anidulafungin. Thus it appears reasonable to investigate the impact of higher doses of caspofungin to improve the results already achieved with this component so far. The maximum tolerated dose (MTD) of caspofungin and the distribution of the drug in patients following administration of doses of 70 mg or more are not yet known. We therefore investigate the safety, tolerability and pharmacokinetics of caspofungin in rising doses in a dose escalation study in adult patients with proven or probable invasive aspergillosis.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Immunocompromised due to hematologic malignancies, bone marrow failure syndromes,

hematopoietic stem cell transplantation, solid organ transplantation, other conditions resulting in severe neutropenia, HIV infection, prolonged corticosteroid therapy, treatment with other immunosuppressive medications, or other immunocompromising conditions that place patients at risk for invasive fungal infections.

- Evidence of proven or probable invasive aspergillosis, by modified EORTC criteria

Exclusion Criteria:

- Concomitant other systemic antifungal agents are not permitted on study.

- Chronic invasive fungal infection, defined as signs/symptoms of invasive fungal

infection present for > 4 weeks preceding entry into study

- Prior systemic therapy of ≥ 4 days with any polyene anti-fungal agent within 14 days

of study enrollment

- Prior systemic therapy of ≥ 4 days with non-polyenes for the current, documented IFI.

Locations and Contacts

University Hospital Gasthuisberg, Leuven 3000, Belgium

Charité - Campus Benjamin Franklin, Berlin 12200, Germany

Klinikum der Universität zu Köln, Köln 50924, Germany

Universitätsklinikum Münster, Münster 48149, Germany

Additional Information

Starting date: October 2006
Last updated: July 25, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017